Results 111 to 115 of about 898 (115)

Plain language summary of the design of the APPEAR-C3G Study: A Study to Learn How Well Iptacopan Works in People with Complement 3 Glomerulopathy

Future Rare Diseases, 2023
Andrew Bomback
exaly  

Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy

Kidney International
Hernán Trimarchi, Guido Junge
exaly  

Factor B inhibitor iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria

Blood Reviews
Jiecan Zhou
exaly  

Targeting the alternative complement pathway by iptacopan abrogates C3 and strongly reduces C5b-9 deposition within glomeruli in IgA nephropathy recurrence after kidney transplantation

American Journal of Transplantation
Ester Gallo, Alberto Mella, Silvia Mingozzi   +2 more
exaly  

Iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria

Expert Opinion on Pharmacotherapy
exaly